Kaku Itoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kaku Itoh has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Misaki Negishi
2 shared publications- Araya Umetsu
Departments of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan
1 shared publication - Fumihito Hikage
Departments of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan
1 shared publication - Hiroshi Ohguro
Departments of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Sapporo 060-8556, Japan
1 shared publication Hiroyasu Katayama
Departments of Ophthalmology, Muroran City General Hospital, Muroran, Japan
1 shared publication- Hiroyasu Katayama
Departments of Ophthalmology, Sapporo Medical University School of Medicine, Hokkaido 060-8556, Japan
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy
Purpose: To compare and evaluate, across different agents, the risk of intraocular pressure (IOP) elevation after anti-VEGF therapy and the accuracy of prefilled syringes. Methods: Total of 175 eyes treated with anti-VEGF drugs were enrolled for this study. An accuracy evaluation of the prefilled syringes was conducted involving 25 participants, comprising 17 physicians and 8 nurses. The anti-VEGF agents including aflibercept 2 mg, aflibercept 8 mg, brolucizumab, faricimab, and ranibizumab-BS were assessed. IOP was measured before, and at 1 and 15 minutes after intravitreal injection, and analyzed separately for each drug. Furthermore, prefilled syringes of aflibercept 2 mg, brolucizumab, and ranibizumab-BS, as well as 1-mL syringes filled with saline solution, were equipped with 30-gauge needles, followed by careful removal of air. The weight of the saline discharged according to the scale marking was measured using an electronic balance. Results: At 1 min after intravitreal injection, the IOP was highest in the aflibercept 2 mg group, with a mean value of 52.8 mmHg. A mild inverse correlation was observed between axial length and IOP elevation at 1 min post-injection, suggesting that eyes with longer axial length exhibited less pronounced IOP increases. In the syringe accuracy analysis, the prefilled syringe of aflibercept 2 mg expelled a significantly larger volume, with a mean of approximately 0.076 mL, compared to other prefilled syringes. Conclusion: Intravitreal injection using the aflibercept 2 mg prefilled syringe may deliver approximately 1.5 times the intended volume into the eye. This may raise safety concerns, such as the risk of transient vision loss due to marked immediate IOP elevation, and may also affect clinical outcomes and the validity of clinical trials.
- 1 March 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Open AccessMeasurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy
Purpose: To compare and evaluate, across different agents, the risk of intraocular pressure (IOP) elevation after anti-VEGF therapy and the accuracy of prefilled syringes. Methods: Total of 175 eyes treated with anti-VEGF drugs were enrolled for this study. An accuracy evaluation of the prefilled syringes was conducted involving 25 participants, comprising 17 physicians and 8 nurses. The anti-VEGF agents including aflibercept 2 mg, aflibercept 8 mg, brolucizumab, faricimab, and ranibizumab-BS were assessed. IOP was measured before, and at 1 and 15 minutes after intravitreal injection, and analyzed separately for each drug. Furthermore, prefilled syringes of aflibercept 2 mg, brolucizumab, and ranibizumab-BS, as well as 1-mL syringes filled with saline solution, were equipped with 30-gauge needles, followed by careful removal of air. The weight of the saline discharged according to the scale marking was measured using an electronic balance. Results: At 1 min after intravitreal injection, the IOP was highest in the aflibercept 2 mg group, with a mean value of 52.8 mmHg. A mild inverse correlation was observed between axial length and IOP elevation at 1 min post-injection, suggesting that eyes with longer axial length exhibited less pronounced IOP increases. In the syringe accuracy analysis, the prefilled syringe of aflibercept 2 mg expelled a significantly larger volume, with a mean of approximately 0.076 mL, compared to other prefilled syringes. Conclusion: Intravitreal injection using the aflibercept 2 mg prefilled syringe may deliver approximately 1.5 times the intended volume into the eye. This may raise safety concerns, such as the risk of transient vision loss due to marked immediate IOP elevation, and may also affect clinical outcomes and the validity of clinical trials.
- Open Access
- 22 August 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (3) , e366-e374
A modified trabeculectomy technique with direct filtration into the Tenon's capsule
- 22 August 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 60 (3) , e366-e374
Open AccessA modified trabeculectomy technique with direct filtration into the Tenon's capsule
- Open Access
- 3 July 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 254, 104-113
Stainability of Acrylic Intraocular Lens With Brilliant Blue G: An In Vitro Study
- 3 July 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 254, 104-113
Open AccessStainability of Acrylic Intraocular Lens With Brilliant Blue G: An In Vitro Study
- Open Access
- 3 January 2023
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 14 (1) , 1-6
A Case of Intraocular Cilium after 25-Gauge Micro-Incision Vitrectomy Surgery
We report a case of intraocular cilium after micro-incision vitrectomy surgery for retinal detachment. A 61-year-old male underwent vitrectomy with cataract surgery for rhegmatogenous retinal detachment. The postoperative course was generally good with no re-detachment, but on examination 3 months later, a cilium was observed on the retina above the fundus. After discussing with the patient, it was decided to take no immediate action and just continuously monitor the patient in order to detect if there was worsening of any of the symptoms. The present case report suggests that foreign bodies such as cilium may stray into the eye through trocar even during vitrectomy. One of the possible causes was the risk of the noncontact wide-angle viewing system.
- 3 January 2023
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 14 (1) , 1-6
Open AccessA Case of Intraocular Cilium after 25-Gauge Micro-Incision Vitrectomy Surgery
We report a case of intraocular cilium after micro-incision vitrectomy surgery for retinal detachment. A 61-year-old male underwent vitrectomy with cataract surgery for rhegmatogenous retinal detachment. The postoperative course was generally good with no re-detachment, but on examination 3 months later, a cilium was observed on the retina above the fundus. After discussing with the patient, it was decided to take no immediate action and just continuously monitor the patient in order to detect if there was worsening of any of the symptoms. The present case report suggests that foreign bodies such as cilium may stray into the eye through trocar even during vitrectomy. One of the possible causes was the risk of the noncontact wide-angle viewing system.
- Open Access
- 5 August 2022
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 13 (2) , 578-583
Bilateral Optic Neuritis after COVID-19 mRNA Vaccination
We report the case of a healthy man who was diagnosed with bilateral optic neuritis after COVID-19 vaccination. A 63-year-old man presented with acute painful blurred vision in his left eye and temporal pain. Eleven days before the appearance of his symptoms, he received the first dose of COVID-19 mRNA vaccination. On examination, his best corrected visual acuity was 20/20 in his right eye and counting fingers in the left eye. Funduscopic examination showed bilateral optic disc swelling, and postcontrast magnetic resonance imaging showed left optic nerve sheath enhancement, consistent with left optic perineuritis and right optic papillitis. After steroid pulse therapy, his visual function and headache showed significant improvement. A few cases of optic neuritis as a side effect of COVID-19 mRNA vaccination were reported. This report provides important information about side effects assumed to be related to the COVID-19 mRNA vaccine.
- 5 August 2022
- Published by S. Karger AG in Case Reports in Ophthalmology
- Vol. 13 (2) , 578-583
Open AccessBilateral Optic Neuritis after COVID-19 mRNA Vaccination
We report the case of a healthy man who was diagnosed with bilateral optic neuritis after COVID-19 vaccination. A 63-year-old man presented with acute painful blurred vision in his left eye and temporal pain. Eleven days before the appearance of his symptoms, he received the first dose of COVID-19 mRNA vaccination. On examination, his best corrected visual acuity was 20/20 in his right eye and counting fingers in the left eye. Funduscopic examination showed bilateral optic disc swelling, and postcontrast magnetic resonance imaging showed left optic nerve sheath enhancement, consistent with left optic perineuritis and right optic papillitis. After steroid pulse therapy, his visual function and headache showed significant improvement. A few cases of optic neuritis as a side effect of COVID-19 mRNA vaccination were reported. This report provides important information about side effects assumed to be related to the COVID-19 mRNA vaccine.
- Open Access
Fatty Acid-Binding Proteins 4 and 5 Are Involved in the Pathogenesis of Retinal Vascular Diseases in Different Manners
This study reports on the pathological significance of the vitreous fatty acid-binding protein (Vt-FABP) 4 and 5, and vascular endothelial growth factor A (Vt-VEGFA) in patients with retinal vascular diseases (RVDs) including proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO). Subjects with PDR (n = 20), RVO (n = 10), and controls (epiretinal membrane, n = 18) who had undergone vitrectomies were enrolled in this study. The levels of Vt-FABP4, Vt-FABP5, and Vt-VEGFA were evaluated by enzyme-linked immunosorbent assays (ELISA). Retinal circulation levels were measured by a laser-speckle flow analyzer (LSFA) and other relevant data were collected. The Vt-FABP5 levels were significantly (p < 0.05) elevated in patients with RVDs compared to control patients. This elevation was more evident in patients with RVO than with PDR. Log Vt-FABP5 was significantly correlated negatively or positively with all the LSFA retinal circulation indexes or Log triglycerides (r = 0.31, p = 0.031), respectively. However, the elevations in the Vt-FABP4 and Vt-VEGFA levels were more evident in the PDR group (p < 0.05) and these factors were correlated positively with Log fasting glucose and negatively with some of the LSFA retinal circulation indexes. Multivariable regression analyses indicated that the LSFA blood flows of the optic disc at baseline was an independent effector with Log Vt-FABP5 other than several possible factors including age, gender, Log triglycerides, Log Vt-FABP4 and Log Vt-VEGFA. These current findings suggest that Vt-FABP5 is involved in the pathogenesis of RVD in a manner that is different from that for Vt-FABP4 and Vt-VEGFA, presumably by regulating retinal circulation.
Open AccessFatty Acid-Binding Proteins 4 and 5 Are Involved in the Pathogenesis of Retinal Vascular Diseases in Different Manners
This study reports on the pathological significance of the vitreous fatty acid-binding protein (Vt-FABP) 4 and 5, and vascular endothelial growth factor A (Vt-VEGFA) in patients with retinal vascular diseases (RVDs) including proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO). Subjects with PDR (n = 20), RVO (n = 10), and controls (epiretinal membrane, n = 18) who had undergone vitrectomies were enrolled in this study. The levels of Vt-FABP4, Vt-FABP5, and Vt-VEGFA were evaluated by enzyme-linked immunosorbent assays (ELISA). Retinal circulation levels were measured by a laser-speckle flow analyzer (LSFA) and other relevant data were collected. The Vt-FABP5 levels were significantly (p < 0.05) elevated in patients with RVDs compared to control patients. This elevation was more evident in patients with RVO than with PDR. Log Vt-FABP5 was significantly correlated negatively or positively with all the LSFA retinal circulation indexes or Log triglycerides (r = 0.31, p = 0.031), respectively. However, the elevations in the Vt-FABP4 and Vt-VEGFA levels were more evident in the PDR group (p < 0.05) and these factors were correlated positively with Log fasting glucose and negatively with some of the LSFA retinal circulation indexes. Multivariable regression analyses indicated that the LSFA blood flows of the optic disc at baseline was an independent effector with Log Vt-FABP5 other than several possible factors including age, gender, Log triglycerides, Log Vt-FABP4 and Log Vt-VEGFA. These current findings suggest that Vt-FABP5 is involved in the pathogenesis of RVD in a manner that is different from that for Vt-FABP4 and Vt-VEGFA, presumably by regulating retinal circulation.